Holen Sie sich die Stockscreener-App
4.24
11.87%
0.45
Handel nachbörslich:
4.24
Schlusskurs vom Vortag:
$3.79
Offen:
$4.03
24-Stunden-Volumen:
3.12M
Relative Volume:
2.03
Marktkapitalisierung:
$1.67B
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-31.98
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
-8.62%
1M Leistung:
+3.67%
6M Leistung:
-13.29%
1J Leistung:
-44.28%
1-Tages-Spanne:
$3.86
$4.355
1-Wochen-Bereich:
$3.675
$4.795
52-Wochen-Spanne:
$3.675
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.24 | 1.67B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
239.53 | 37.82B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
59.35 | 10.90B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
65.22 | 8.97B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
91.33 | 7.61B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
40.49 | 6.83B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GoodRx Earnings Call: Mixed Sentiment with Growth and Challenges - TipRanks
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates - MSN
GoodRx (GDRX) Stock Surges on Quarterly Earnings and Guidance Up - GuruFocus
Why GoodRx Holdings Stock Triumphed on Thursday - Yahoo Finance
Medicare Changes on the Way? - marketscreener.com
Transcript : GoodRx Holdings, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
GDRX vs. PGNY: Which Stock Should Value Investors Buy Now? - Yahoo Finance
Is GoodRx (GDRX) a Great Value Stock Right Now? - Yahoo Finance
Earnings call transcript: GoodRx stock surges after Q1 2025 earnings - Investing.com
Compared to Estimates, GoodRx (GDRX) Q1 Earnings: A Look at Key Metrics - MSN
BofA cuts GoodRx stock price target to $4 on MAC concerns - Investing.com Nigeria
Leerink maintains GoodRx stock Outperform with $9 target - Investing.com Australia
Leerink maintains GoodRx stock Outperform with $9 target By Investing.com - Investing.com Nigeria
BofA Adjusts Price Target for GoodRx (GDRX) Amid Mixed Earnings Report | GDRX Stock News - GuruFocus
KeyBanc maintains GoodRx stock Overweight with $6 target - Investing.com
GoodRx Holdings Inc. (GDRX) PT Lowered to $4 at BofA Securities - StreetInsider
GoodRx Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GoodRx’s (NASDAQ:GDRX) Q1 Earnings Results: Revenue In Line With Expectations, Stock Jumps 10.3% - Yahoo Finance
GoodRx Holdings Swings To Q1 Profit - Nasdaq
GoodRx Holdings Inc Reports Q1 2025 Earnings: EPS of $0.03 Misses Estimate, Revenue of $203 Million Slightly Beats Estimate - GuruFocus
GoodRx Holdings, Inc. SEC 10-Q Report - TradingView
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY25 Revenue Guidance - StreetInsider
GoodRx Reports First Quarter 2025 Results - Business Wire
GoodRx Holdings Inc (GDRX) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
GoodRx Holdings, Inc. (GDRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Stock Has Shown A Decent Performance: Have Financials A Role To Play? - Yahoo Finance
LPL Financial LLC Increases Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Wells Fargo Adjusts Price Target for GoodRx (GDRX), Cites Compet - GuruFocus
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Shareholders that Lost Money on GoodRx Holdings, Inc.(GDRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Attorney General Fitch secures restraining order against GoodRx and affiliates over pharmacy reimbursements - Picayune Item
Private equity firms who hold 55% of GoodRx Holdings, Inc. (NASDAQ:GDRX) gained 3.6%, institutions profited as well - simplywall.st
GoodRx Beats Investor Suit Over Kroger-Linked Biz - Law360
3 Reasons to Sell GDRX and 1 Stock to Buy Instead - The Globe and Mail
Why GoodRx Holdings (GDRX) Is Among the Best Telehealth Stocks to Buy Now - Insider Monkey
TD Cowen Sticks to Their Buy Rating for GoodRx Holdings (GDRX) - The Globe and Mail
Truist Cuts Price Target on GoodRx Holdings to $5.50 From $6.50, Keeps Hold Rating - marketscreener.com
GoodRx Announces Date for First Quarter 2025 Earnings Release an - GuruFocus
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call - Bluefield Daily Telegraph
GoodRx Sets Q1 Earnings Date: What Healthcare Investors Should Watch - Stock Titan
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform - Nasdaq
Levi & Korsinsky Notifies GoodRx Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineGDRX - ACCESS Newswire
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.18 Average Price Target from Brokerages - MarketBeat
GoodRx Stock Hits 52-Week Low at $4.09 Amid Market Challenges - Investing.com Australia
GoodRx Stock Hits 52-Week Low at $4.09 Amid Market Challenges By Investing.com - Investing.com South Africa
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
2.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):